Novo Nordisk news

Montreal, Canada – New data on patient treatment satisfaction from the LEAD™ 6 trial presented today at the 20th World Diabetes Congress (International Diabetes Federation) shows that patients have higher overall treatment satisfaction with liraglutide than they do with exenatide.

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Vienna, Austria - Data from a new study presented today at the annual meeting of the European Association for the Study of Diabetes (EASD) shows that type 2 diabetes patients starting insulin treatment with once-daily injection of NovoMix® 30 (biphasic insulin aspart) achieve a significantly greater HbA1c reduction compared to patients starting with a daily injection of insulin glargine.

In continuation of the company's announcement dated 6 August 2009 concerning a planned share repurchase programme, and pursuant to Section 204.25 of the New York Stock Exchange Listed Company Manual, this is to report that Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates on 30 September 2009 owned 27,723,808 of its own B shares of DKK 1, corresponding to a total nominal value of DKK 27

Vienna, Austria - New data from the extension phase of the LEAD™ 6 phase 3b study presented today at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD) shows that patients with type 2 diabetes further improved their treatment outcome by switching from two daily injections of Byetta® (exenatide, 10 µg dose) to one daily injection of Victoza® (liraglutide, 1.8 mg do

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

Novo Nordisk today announced that formal feedback from the United States Food and Drug Administration (FDA) regarding liraglutide, a once-daily human GLP-1 analogue, has been deferred until the fourth quarter of 2009. Novo Nordisk continues the constructive dialogue with the FDA regarding the regulatory process for liraglutide.

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.